Comments
Veeda Clinical Research has filed preliminary papers with capital markets regulator Sebi to raise a little over ₹831 crore through an initial public offering (IPO).
The initial share sale will consist of the issuing fresh equity shares worth up to ₹331.60 crore and an offer for sale (OFS) of ₹500 crore by promoters and existing shareholders, according to the draft red herring prospectus (DRHP).
Investors participating in OFS include CX Alternative Investment Fund aggregating up to ₹8.08 crore, ₹90.19 crore by Arabelle Financial Services, ₹259.77 crore by Bondway Investment Inc., ₹0.04 crore by Stevey International Corporation and ₹141.93 crore by Basil Private Limited.
The company intends to utilise net proceeds from the fresh issue for repayment of the debt, funding capital expenditure, further acquiring subsidiary Bioneeds India, funding working capital requirements, and general corporate purposes.
In June, the Ahmedabad-based company, which is backed by CX Partners, announced raising USD 16 million from PE firm Sabre Partners, and high networth individuals including Pranab Mody of JB Chemicals, Havells India family office, Nikhil Vora of Sixth Sense Ventures and Arjun Bhartia of Jubilant Group among others.
Furthermore, to support its capabilities and offer top-notch clinical service for novel drugs, Veeda acquired a 50.1 per cent stake in Bangalore-based Bioneeds India, after acquiring a substantial minority stake in the company in March and July 2021.
Veeda, grown from a single facility in 2004 to have four facilities and the capability to process 1 lakh samples per month, is one of India’s leading independent full-service clinical research organisation (CRO).
It specialises in the focused segment of bio availability/bio equivalence (BA/BE) studies. In addition to BA/BE tests, it offers a broad range of services across most drug development and drug launch value-chain throughout the global markets, including North America, Europe and Asia.
As of March 2021, Veeda has conducted more than 3,500 trials and developed over 1,000 bio-analytical methods spread across generics. It has also completed over 85 global inspections with regulatory authorities, including USFDA, WHO and DGCI.
For fiscal 2021, Veeda Clinical Research reported revenue of ₹195.81 crore and net profit of ₹62.97 crore.
SBI Capital Markets, ICICI Securities, JM Financial and Systematix Corporate Services are the book running lead managers to the issue.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.